Company Overview and News

3
Microsoft (MSFT) Outpaces Stock Market Gains: What You Should Know

2018-09-12 zacks
Microsoft (MSFT - Free Report) closed the most recent trading day at $111.71, moving +0.42% from the previous trading session. This change outpaced the S&P 500's 0.04% gain on the day. Elsewhere, the Dow gained 0.11%, while the tech-heavy Nasdaq lost 0.23%.
OXM MLHR ESNC MSFT 514414 OXFORDIN RHT

4
Celgene (CELG) Stock Sinks As Market Gains: What You Should Know

2018-09-12 zacks
In the latest trading session, Celgene (CELG - Free Report) closed at $86.80, marking a -0.45% move from the previous day. The stock lagged the S&P 500's daily gain of 0.04%. Meanwhile, the Dow gained 0.11%, and the Nasdaq, a tech-heavy index, lost 0.23%.
OXM MLHR CELG ESNC 514414 OXFORDIN RHT

2
Amazon (AMZN) Outpaces Stock Market Gains: What You Should Know

2018-09-12 zacks
In the latest trading session, Amazon (AMZN - Free Report) closed at $1,990, marking a +0.14% move from the previous day. This change outpaced the S&P 500's 0.04% gain on the day. Meanwhile, the Dow gained 0.11%, and the Nasdaq, a tech-heavy index, lost 0.23%.
OXM MLHR ESNC 514414 OXFORDIN RHT

3
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know

2018-09-12 zacks
In the latest trading session, Canopy Growth Corporation (CGC - Free Report) closed at $51.05, marking a -0.31% move from the previous day. The stock lagged the S&P 500's daily gain of 0.04%. Meanwhile, the Dow gained 0.11%, and the Nasdaq, a tech-heavy index, lost 0.23%.
OXM WEED MLHR ESNC 514414 OXFORDIN CGC RHT

3
Broadcom Inc. (AVGO) Stock Sinks As Market Gains: What You Should Know

2018-09-12 zacks
Broadcom Inc. (AVGO - Free Report) closed the most recent trading day at $229.89, moving -1.14% from the previous trading session. This move lagged the S&P 500's daily gain of 0.04%. Elsewhere, the Dow gained 0.11%, while the tech-heavy Nasdaq lost 0.23%.
OXM MLHR AVGO ESNC 514414 OXFORDIN BRCM RHT

2
Lululemon (LULU) Stock Sinks As Market Gains: What You Should Know

2018-09-12 zacks
In the latest trading session, Lululemon (LULU - Free Report) closed at $153.01, marking a -0.09% move from the previous day. The stock lagged the S&P 500's daily gain of 0.04%. Elsewhere, the Dow gained 0.11%, while the tech-heavy Nasdaq lost 0.23%.
OXM MLHR ESNC 514414 OXFORDIN RHT

3
Paycom Software (PAYC) Stock Sinks As Market Gains: What You Should Know

2018-09-12 zacks
In the latest trading session, Paycom Software (PAYC - Free Report) closed at $158.89, marking a -0.01% move from the previous day. This change lagged the S&P 500's 0.04% gain on the day. Elsewhere, the Dow gained 0.11%, while the tech-heavy Nasdaq lost 0.23%.
OXM MLHR ESNC 514414 OXFORDIN RHT PAYC

3
Apple (AAPL) Stock Sinks As Market Gains: What You Should Know

2018-09-12 zacks
Apple (AAPL - Free Report) closed the most recent trading day at $221.07, moving -1.24% from the previous trading session. This move lagged the S&P 500's daily gain of 0.04%. Elsewhere, the Dow gained 0.11%, while the tech-heavy Nasdaq lost 0.23%.
OXM MLHR AAPL ESNC 514414 OXFORDIN RHT

4
Intel (INTC) Flat As Market Gains: What You Should Know

2018-09-12 zacks
Intel (INTC - Free Report) closed the most recent trading day at $44.93, making no change from the previous trading session. The stock lagged the S&P 500's daily gain of 0.04%. Elsewhere, the Dow gained 0.11%, while the tech-heavy Nasdaq lost 0.23%.
OXM MLHR ESNC 514414 OXFORDIN INTC RHT

2
Oxford Industries (OXM) Meets Q2 Earnings Estimates

2018-09-12 zacks
Oxford Industries (OXM - Free Report) came out with quarterly earnings of $1.83 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.44 per share a year ago. These figures are adjusted for non-recurring items.
OXM MLHR ESNC 514414 OXFORDIN RHT

5
Tailored Brands (TLRD) Meets Q2 Earnings Estimates

2018-09-12 zacks
Tailored Brands (TLRD - Free Report) came out with quarterly earnings of $1.07 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.
OXM MLHR ESNC 514414 OXFORDIN TLRD RHT

2
EnSync Inc (ESNC) Q4 Earnings Preview: What to Expect

2018-09-12 zacks
Wall Street expects a year-over-year increase in earnings on higher revenues when EnSync Inc (ESNC - Free Report) reports results for the quarter ended June 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
ESNC

4
ESNC / EnSync, Inc. 424B5 (Prospectus)

2018-09-06 sec.gov - 2
Filed Pursuant to Rule 424(b)(5) Registration No. 333-218935 PROSPECTUS SUPPLEMENT
ESNC

4
ESNC / EnSync, Inc. FORM 8-K (Current Report)

2018-09-06 sec.gov - 2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washin
ESNC

13
ESNC / EnSync, Inc. 8-K (Current Report)

2018-06-21 sec.gov - 11
UNITED STATES
ESNC

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 29359T102